Democratising clinical genomics while protecting data privacy
Sophia Genetics co-founder and CEO, Jurgi Camblong, tackles issues of privacy and security for healthcare patient data...
List view / Grid view
Articles
How Ketamine could cure depression
Amorsa Therapeutics' CSO, Michael Palfreyman, discusses how the party drug Ketamine can be used to target NMDA receptors and treat depression...
How imaging biomarkers are transforming drug development
Drug developers sometimes think of imaging as an emerging discipline, full of esoteric technologies of marginal relevance to real-world clinical drug development. In fact, the opposite is true: imaging measurements (imaging biomarkers) are used daily in drug development and in personalised medicine. They assess target engagement and receptor occupancy in…
Draper and Pfizer partner on human organ-on-a-chip technology
The companies will collaborate to create unique versions of Draper’s Microphysiological Systems (MPS) technology, with the aim of creating more effective disease models...
High-throughput screening platforms incorporating physiologically relevant 3-D models
Two-dimensional monolayer cell proliferation assays for cancer drug discovery have enabled large-scale screens. But they represent a simplified view of oncogenes or tumour suppressor genes as the genetic drivers of cancer cell proliferation.
Industrialising organoids for the next generation of drug discovery
New synthetic 3D gel technology for cell culture promises to unlock the potential of ‘mini-organs’ for industrial drug discovery.
Clinical optimism for antagonists targeting certain ion channels
Adenosine triphosphate (ATP)-gated ion channels serve important neurophysiological functions and have been an attractive class of drug target for a decade...
Translational proteomics: from the bench to the bedside
Understanding how a cell responds to different stimuli producing diverse protein profiles can provide information about cell signalling pathways, generating more specific treatments...
Tackling the spread of pathogens in transport hubs
Ilpo Kulmala, Principal Scientist at VTT Ltd, explains the role that transportation plays in the spread of infectious diseases...
Exploring the need for mutation-specific treatments in cystic fibrosis
Despite that over 1,900 mutations of the cystic fibrosis transmembrane conductance regulator cause cystic fibrosis, only two treatment options exist.
Screening In-Depth Focus 2016
In this Screening In-Depth Focus, scientists from the Assay Development and Screening Platform of Helmholtz Zentrum München provide an overview of different high-throughput screening (HTS)-applicable assay types that can be applied to drug discovery campaigns. Plus an interview with Lee Babiss, CEO of drug discovery firm X-Rx, on the benefits…
Personalised Medicines In-Depth Focus 2016
In this Personalised Medicines In-Depth Focus, Dr Adrian Harel talks about the importance of developing a diagnostic test and better treatments for traumatic brain injury. Plus, Caroline Richards, Editor of Drug Target Review explores the need for mutation specific treatments in cystic fibrosis...
Next-Generation Sequencing In-Depth Focus 2016
NGS technologies have been employed in a wide range of areas in drug discovery, including drug target identification, biomarker discovery and biopharmaceutics development. Pushpanathan Muthuirulan of the National Institutes of Health gives us an overview of this in his article in our NGS In-Depth Focus. Meanwhile, the possibilities that RNA-Seq…
Drug Target Review – Issue #4 2016
11 December 2016 | By Drug Target Review
Included in this issue: Profiling proteins produced by cells to provide information about cell signalling pathways; HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes; Preventing the spread of infectious diseases in transport hubs...
Valid biomarker signatures from liquid biopsies – how to standardise NGS
The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…